Literature DB >> 28225205

Greater endurance capacity and improved dyspnoea with acute oxygen supplementation in idiopathic pulmonary fibrosis patients without resting hypoxaemia.

Leona M Dowman1,2,3,4, Christine F McDonald2,3,5, Steven Bozinovski6, Ross Vlahos6, Rebecca Gillies1,3, Dodie Pouniotis3,6, Catherine J Hill3,4, Nicole S L Goh2,3, Anne E Holland1,3,7.   

Abstract

BACKGROUND AND
OBJECTIVE: Supplemental oxygen is commonly prescribed in patients with idiopathic pulmonary fibrosis (IPF), although its benefits have not been proven. The aims of this study were to investigate the effect of oxygen on oxidative stress, cytokine production, skeletal muscle metabolism and physiological response to exercise in IPF.
METHODS: Eleven participants with IPF received either oxygen, at an FiO2 of 0.50, or compressed air for 1 h at rest and during a cycle endurance test at 85% of peak work rate. Blood samples collected at rest and during exercise were analysed for markers of oxidative stress, skeletal muscle metabolism and cytokines. The protocol was repeated a week later with the alternate intervention.
RESULTS: Compared with air, oxygen did not adversely affect biomarker concentrations at rest and significantly improved endurance time (mean difference = 99 ± 81s, P = 0.002), dyspnoea (-1 ± 1 U, P = 0.02), systolic blood pressure (BP; -11 ± 11 mm Hg, P = 0.006), nadir oxyhaemoglobin saturation (SpO2 ; 8 ± 6%, P = 0.001), SpO2 at 2-min (7 ± 6%, P = 0.003) and 5-min isotimes (5 ± 3, P < 0.001) and peak exercise xanthine concentrations (-42 ± 73 µmol/L, P = 0.03). Air significantly increased IL-10 (5 ± 5 pg/mL, P = 0.04) at 2-min isotime. Thiobarbituric acid-reactive substances (TBARs), IL-6, TNF-α, creatine kinase, lactate, heart rate and fatigue did not differ between the two interventions at any time point.
CONCLUSION: In patients with IPF, breathing oxygen at FiO2 of 0.50 at rest seems safe. During exercise, oxygen improves exercise tolerance, alleviates exercise-induced hypoxaemia and reduces dyspnoea. A potential relationship between oxygen administration and improved skeletal muscle metabolism should be explored in future studies.
© 2017 Asian Pacific Society of Respirology.

Entities:  

Keywords:  exercise; idiopathic pulmonary fibrosis; metabolism; oxidative stress; oxygen

Mesh:

Substances:

Year:  2017        PMID: 28225205     DOI: 10.1111/resp.13002

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  8 in total

1.  Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity.

Authors:  Hana Serajeddini; Paola Rogliani; Marco Mura
Journal:  Lung       Date:  2018-08-27       Impact factor: 2.584

Review 2.  Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF).

Authors:  Shigeki Saito; Ala Alkhatib; Jay K Kolls; Yasuhiro Kondoh; Joseph A Lasky
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

3.  Does ambulatory oxygen improve quality of life in patients with fibrotic lung disease? Results from the AmbOx trial.

Authors:  Andrew W Creamer; Shaney L Barratt
Journal:  Breathe (Sheff)       Date:  2019-06

Review 4.  Management of Chronic Respiratory Failure in Interstitial Lung Diseases: Overview and Clinical Insights.

Authors:  Paola Faverio; Federica De Giacomi; Giulia Bonaiti; Anna Stainer; Luca Sardella; Giulia Pellegrino; Giuseppe Francesco Sferrazza Papa; Francesco Bini; Bruno Dino Bodini; Mauro Carone; Sara Annoni; Grazia Messinesi; Alberto Pesci
Journal:  Int J Med Sci       Date:  2019-06-10       Impact factor: 3.738

5.  Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand.

Authors:  Adelle S Jee; Robert Sheehy; Peter Hopkins; Tamera J Corte; Christopher Grainge; Lauren K Troy; Karen Symons; Lissa M Spencer; Paul N Reynolds; Sally Chapman; Sally de Boer; Taryn Reddy; Anne E Holland; Daniel C Chambers; Ian N Glaspole; Helen E Jo; Jane F Bleasel; Jeremy P Wrobel; Leona Dowman; Matthew J S Parker; Margaret L Wilsher; Nicole S L Goh; Yuben Moodley; Gregory J Keir
Journal:  Respirology       Date:  2020-11-24       Impact factor: 6.424

6.  Impact of high-flow oxygen therapy during exercise in idiopathic pulmonary fibrosis: a pilot crossover clinical trial.

Authors:  Diana Badenes-Bonet; Pilar Cejudo; Anna Rodó-Pin; Clara Martín-Ontiyuelo; Roberto Chalela; Jose Antonio Rodríguez-Portal; Rosa Vázquez-Sánchez; Joaquim Gea; Xavier Duran; Oswaldo Antonio Caguana; Diego Agustín Rodriguez-Chiaradia; Eva Balcells
Journal:  BMC Pulm Med       Date:  2021-11-08       Impact factor: 3.317

Review 7.  IPF Respiratory Symptoms Management - Current Evidence.

Authors:  Piotr Janowiak; Amelia Szymanowska-Narloch; Alicja Siemińska
Journal:  Front Med (Lausanne)       Date:  2022-07-28

8.  Hyperbaric Oxygen Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice.

Authors:  Yuan Yuan; Yali Li; Guoqiang Qiao; Yilu Zhou; Zijian Xu; Charlotte Hill; Zhenglin Jiang; Yihua Wang
Journal:  Front Mol Biosci       Date:  2021-06-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.